InsiderSignal.AI

InsiderSignal.ai

ONCY - Oncolytics Biotech Inc

Insider Purchase by Andrews Patricia S (Dir)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

1 week ago, Andrews Patricia S, serving as Dir at Oncolytics Biotech Inc (ONCY), purchased 35,400 shares at $0.86 per share, for a total transaction value of $30,292.00. Following this transaction, Andrews Patricia S now holds 78,128 shares of ONCY.

This purchase represents a 83.00% increase in Andrews Patricia S's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Thursday, February 12, 2026 and publicly disclosed via SEC Form 4 filing on Friday, February 13, 2026, 1 day after the trade was made.

Oncolytics Biotech Inc operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

Andrews Patricia S

Dir

Patricia S. Andrews is an accomplished biopharmaceutical executive and public company board member with extensive experience in corporate strategy, product commercialization, and business development.[[1]](https://www.prnewswire.com/news-releases/oncolytics-biotech-appoints-patricia-s-andrews-to-its-board-of-directors-302029215.html)[[2]](https://oncolyticsbiotech.com/press_releases/oncolytics-biotech-appoints-patricia-s-andrews-to-its-board-of-directors/) She was appointed to the Board of Directors of Oncolytics Biotech Inc. (ONCY) as a Director in January 2024, bringing her expertise in oncology trials and partnerships to support the company's advancement of pelareorep toward registrational studies in breast and pancreatic cancers.[[1]](https://www.prnewswire.com/news-releases/oncolytics-biotech-appoints-patricia-s-andrews-to-its-board-of-directors-302029215.html)[[2]](https://oncolyticsbiotech.com/press_releases/oncolytics-biotech-appoints-patricia-s-andrews-to-its-board-of-directors/)[[5]](https://www.sahmcapital.com/news/content/oncolytics-biotech-inc-files-initial-beneficial-ownership-statement-for-director-patricia-s-andrews-2026-01-03) Andrews previously served as Chief Executive Officer of Sumitomo Pharma Oncology, Inc., leading integration efforts, completing three Phase 3 trials, and expanding the pipeline from two to eight programs.[[1]](https://www.prnewswire.com/news-releases/oncolytics-biotech-appoints-patricia-s-andrews-to-its-board-of-directors-302029215.html)[[2]](https://oncolyticsbiotech.com/press_releases/oncolytics-biotech-appoints-patricia-s-andrews-to-its-board-of-directors/) Before that, as Chief Commercial Officer at Incyte, she oversaw the launch of Jakafi® for myelofibrosis and key licensing deals with Novartis and Eli Lilly.[[1]](https://www.prnewswire.com/news-releases/oncolytics-biotech-appoints-patricia-s-andrews-to-its-board-of-directors-302029215.html)[[2]](https://oncolyticsbiotech.com/press_releases/oncolytics-biotech-appoints-patricia-s-andrews-to-its-board-of-directors/) Earlier, she spent 17 years at Pfizer, rising to Vice President and General Manager of the U.S. Oncology Business Unit, where she launched Sutent® as the market leader in renal cell carcinoma and revitalized Camptosar® sales.[[1]](https://www.prnewswire.com/news-releases/oncolytics-biotech-appoints-patricia-s-andrews-to-its-board-of-directors-302029215.html)[[2]](https://oncolyticsbiotech.com/press_releases/oncolytics-biotech-appoints-patricia-s-andrews-to-its-board-of-directors/) She currently serves as a Director and Audit Committee member at GlycoMimetics, aiding its first Phase 3 study and commercialization preparations.[[1]](https://www.prnewswire.com/news-releases/oncolytics-biotech-appoints-patricia-s-andrews-to-its-board-of-directors-302029215.html)[[2]](https://oncolyticsbiotech.com/press_releases/oncolytics-biotech-appoints-patricia-s-andrews-to-its-board-of-directors/) Andrews holds an MBA from the University of Michigan and a BA from Brown University.[[1]](https://www.prnewswire.com/news-releases/oncolytics-biotech-appoints-patricia-s-andrews-to-its-board-of-directors-302029215.html)

View full insider profile →

Trade Price

$0.86

Quantity

35,400

Total Value

$30,292.00

Shares Owned

78,128

Trade Date

Thursday, February 12, 2026

10 days ago

SEC Filing Date

Friday, February 13, 2026

Filed 1 day after trade

HEALTHCAREBIOTECHNOLOGY

About Oncolytics Biotech Inc

Company Overview

No company information available
View news mentioning ONCY

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/3943856

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime